TY - JOUR
T1 - Mechanisms of persistent NF-kappa B activity in the bronchi of an animal model of asthma
AU - Bureau, F
AU - Delhalle, S
AU - Bonizzi, G
AU - Fiévez, L
AU - Dogné, S
AU - Kirschvink, N
AU - Vanderplasschen, A
AU - Merville, M P
AU - Bours, V
AU - Lekeux, P
PY - 2000/11/15
Y1 - 2000/11/15
N2 - In most cells trans-activating NF-kappaB induces many inflammatory proteins as well as its own inhibitor, IkappaB-alpha, thus assuring a transient response upon stimulation. However, NF-kappaB-dependent inflammatory gene expression is persistent in asthmatic bronchi, even after allergen eviction. In the present report we used bronchial brushing samples (BBSs) from heaves-affected horses (a spontaneous model of asthma) to elucidate the mechanisms by which NF-kappaB activity is maintained in asthmatic airways. NF-kappaB activity was high in granulocytic and nongranulocytic BBS cells. However, NF-kappaB activity highly correlated to granulocyte percentage and was only abrogated after granulocytic death in cultured BBSs. Before granulocytic death, NF-kappaB activity was suppressed by simultaneous addition of neutralizing anti-IL-1beta and anti-TNF-alpha Abs to the medium of cultured BBSs. Surprisingly, IkappaB-beta, whose expression is not regulated by NF-kappaB, unlike IkappaB-alpha, was the most prominent NF-kappaB inhibitor found in BBSs. The amounts of IkappaB-beta were low in BBSs obtained from diseased horses, but drastically increased after addition of the neutralizing anti-IL-1beta and anti-TNF-alpha Abs. These results indicate that sustained NF-kappaB activation in asthmatic bronchi is driven by granulocytes and is mediated by IL-1beta and TNF-alpha. Moreover, an imbalance between high levels of IL-1beta- and TNF-alpha-mediated IkappaB-beta degradation and low levels of IkappaB-beta synthesis is likely to be the mechanism preventing NF-kappaB deactivation in asthmatic airways before granulocytic death.
AB - In most cells trans-activating NF-kappaB induces many inflammatory proteins as well as its own inhibitor, IkappaB-alpha, thus assuring a transient response upon stimulation. However, NF-kappaB-dependent inflammatory gene expression is persistent in asthmatic bronchi, even after allergen eviction. In the present report we used bronchial brushing samples (BBSs) from heaves-affected horses (a spontaneous model of asthma) to elucidate the mechanisms by which NF-kappaB activity is maintained in asthmatic airways. NF-kappaB activity was high in granulocytic and nongranulocytic BBS cells. However, NF-kappaB activity highly correlated to granulocyte percentage and was only abrogated after granulocytic death in cultured BBSs. Before granulocytic death, NF-kappaB activity was suppressed by simultaneous addition of neutralizing anti-IL-1beta and anti-TNF-alpha Abs to the medium of cultured BBSs. Surprisingly, IkappaB-beta, whose expression is not regulated by NF-kappaB, unlike IkappaB-alpha, was the most prominent NF-kappaB inhibitor found in BBSs. The amounts of IkappaB-beta were low in BBSs obtained from diseased horses, but drastically increased after addition of the neutralizing anti-IL-1beta and anti-TNF-alpha Abs. These results indicate that sustained NF-kappaB activation in asthmatic bronchi is driven by granulocytes and is mediated by IL-1beta and TNF-alpha. Moreover, an imbalance between high levels of IL-1beta- and TNF-alpha-mediated IkappaB-beta degradation and low levels of IkappaB-beta synthesis is likely to be the mechanism preventing NF-kappaB deactivation in asthmatic airways before granulocytic death.
KW - Airway Obstruction/immunology
KW - Animals
KW - Asthma/immunology
KW - Bronchi/immunology
KW - Bronchoalveolar Lavage Fluid/cytology
KW - Cell Death
KW - Cell Survival
KW - Cells, Cultured
KW - DNA-Binding Proteins/antagonists & inhibitors
KW - Dimerization
KW - Disease Models, Animal
KW - Granulocytes/metabolism
KW - Horse Diseases/immunology
KW - Horses
KW - I-kappa B Proteins
KW - Immune Sera/pharmacology
KW - Interleukin-1/immunology
KW - Leukocyte Count
KW - NF-kappa B/antagonists & inhibitors
KW - Transcription Factor RelA
KW - Tumor Necrosis Factor-alpha/immunology
U2 - 10.4049/jimmunol.165.10.5822
DO - 10.4049/jimmunol.165.10.5822
M3 - Article
C2 - 11067942
SN - 0022-1767
VL - 165
SP - 5822
EP - 5830
JO - Journal of immunology
JF - Journal of immunology
IS - 10
ER -